Inozyme Pharma presents positive interim data on INZ-701 at CHOP Cardiology 2025
Inozyme Pharma Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases affecting bone health and blood vessels, has presented promising ... Read More
Inozyme Pharma acquires Alexion’s ENPP1 gene deficiency program assets
Inozyme Pharma said that it has acquired Alexion Pharmaceuticals’ intellectual property and assets focused on ENPP1 gene deficiencies for an undisclosed price. The acquisition is ... Read More